Home About Us Contact Us

 

Table of Content Volume 14 Issue 2 - May 2020


A study prevalence ocular comorbidity among diabetes patients as per the glycemic control at tertiary health care center

 

Manish Pendse1, Priyadarshini Cholera2*

 

1,2Associate Professor, Department of Medicine, D Y Patil Medical College, Nerul Navi Mumbai, Maharashtra, INDIA.

Email: drmanishpendse@gmail.com

 

Abstract              Background: Globally, type 2 diabetes mellitus (T2DM) has become one of the most important chronic public health problems. Aims and Objective : To study prevalence ocular comorbidities among dibetes patients as per the glycemic control at tertiary health care center Methodology: This was a cross-sectional study carried out in the department of the Ophthalmology during the one year period i.e. June 2018 to June 2019 in the one year period there were 122 patients with various ocular co-morbidity were included into the study by taking the written and explained consent. All details of the patients like age, sex noted. The statistical analysis was done Chi-square test and analysed by SPSS software. Result: Majority of the patients were in the age group of >70 were 27.87%, followed by 60-70 were 23.77%, 50-60 were 19.67%, 40-50 were 15.57%, 30-40 were 9.84%, 20-30 were 3.28%. The majority of the patients were Male i.e. 56.56% and female were 43.44%. The prevalence of Various Ocular morbidities like co-morbidity like Diabetic retinopathy, Refractive errors, Cataract, Corneal ulcers , Uveitis (Iriodocyclitis) Diminished vision , Stye(Infection of Eyelid) were significantly higher and significantly lesser No. of patients with No any Ocular morbidity were found the patients with Glycemic control Excellent (HbA1C <6) this was statistically significant (X2=83.55,df=14,p<0.0001). Conclusion: It can be concluded from our study that prevalence various ocular co-morbidities were significantly higher among the patients with poor Glycemic control and lesser among with Glycemic control Excellent and Good.

Key words: ocular comorbidities, glycemic control, HbA1C, type-II DM.